Pila Pharma AB (publ) (PILA.ST)

STO Healthcare Biotechnology

Pila Pharma AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Malmö, SN, SE. The stock last traded at $1.72, down 1.15% on the session, giving a market capitalisation of $78.6M. Its beta of -0.30 implies it has historically moved less than the broad market.

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.

Pila Pharma AB (publ) is most often compared with the following Healthcare names: